2025-2031 Global Oligonucleotide Conjugates Industry Research & Trends Analysis Report- YH Research

日本语 | 中文

Home > Reports >Medical Care > 2025-2031 Global Oligonucleotide Conjugates Industry Research & Trends Analysis Report

2025-2031 Global Oligonucleotide Conjugates Industry Research & Trends Analysis Report

Publication Date: 2025-12-05
Report Id: 2470848
Industry: Medical Care
Report Page: 140
Chart: 136

PDF Download

Publication Date: 2025-12-05
Report Id: 2470848
Industry: Medical Care
Report Page: 140
Chart: 136

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Product Overview and Scope of Oligonucleotide Conjugates
1.2 Global Oligonucleotide Conjugates Market Size and Forecast
1.3 China Oligonucleotide Conjugates Market Size and Forecast
1.4 China Percentage in Global Market
1.4.1 By Revenue, China Oligonucleotide Conjugates Share in Global Market, 2020-2031
1.4.2 Oligonucleotide Conjugates Market Size: China VS Global, 2020-2031
1.5 Oligonucleotide Conjugates Market Dynamics
1.5.1 Oligonucleotide Conjugates Market Drivers
1.5.2 Oligonucleotide Conjugates Market Restraints
1.5.3 Oligonucleotide Conjugates Industry Trends
1.5.4 Oligonucleotide Conjugates Industry Policy

2 Competitive Landscape by Company
2.1 Global Oligonucleotide Conjugates Revenue by Company, 2020-2025
2.2 Global Oligonucleotide Conjugates Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Oligonucleotide Conjugates Concentration Ratio
2.4 Global Oligonucleotide Conjugates Mergers & Acquisitions, Expansion Plans
2.5 Global Oligonucleotide Conjugates Manufacturers Product Type
2.6 Global Geographic Distribution of Oligonucleotide Conjugates Companies

3 China Competitive Situation by Company
3.1 China Oligonucleotide Conjugates Revenue by Company, 2020-2025
3.2 China Oligonucleotide Conjugates Oligonucleotide Conjugates Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.3 China Oligonucleotide Conjugates Market, Revenue Percentage of Local Players VS Foreign Players (2020-2031)

4 Industry Chain Analysis
4.1 Oligonucleotide Conjugates Industry Chain
4.2 Oligonucleotide Conjugates Upstream Analysis
4.3 Oligonucleotide Conjugates Midstream Analysis
4.4 Oligonucleotide Conjugates Downstream Analysis

5 Sights by Type
5.1 Oligonucleotide Conjugates Classification by Type
5.1.1 Oligonucleotide-Peptide
5.1.2 Oligonucleotide-Antibody
5.1.3 Oligonucleotide-Lipid
5.1.4 Oligonucleotide-Toxin
5.1.5 Oligonucleotide-GalNAc
5.1.6 Other
5.2 by Type, Global Oligonucleotide Conjugates Market Size & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Oligonucleotide Conjugates Market Size, 2020-2031

6 Sights by Oligonucleotide Types
6.1 Oligonucleotide Conjugates Classification by Oligonucleotide Types
6.1.1 siRNA
6.1.2 ASO
6.1.3 Others
6.2 by Oligonucleotide Types, Global Oligonucleotide Conjugates Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Oligonucleotide Types, Global Oligonucleotide Conjugates Market Size, 2020-2031

7 Sights by Application
7.1 Oligonucleotide Conjugates Segment by Application
7.1.1 Gene Therapy
7.1.2 Drug Delivery
7.1.3 Vaccine Development
7.2 by Application, Global Oligonucleotide Conjugates Market Size & CAGR, 2020 VS 2024 VS 2031
7.3 by Application, Global Oligonucleotide Conjugates Market Size, 2020-2031

8 Sights by Region
8.1 By Region, Global Oligonucleotide Conjugates Market Size, 2020 VS 2024 VS 2031
8.2 By Region, Global Oligonucleotide Conjugates Market Size, 2020-2031
8.3 North America
8.3.1 North America Oligonucleotide Conjugates Market Size & Forecasts, 2020-2031
8.3.2 By Country, North America Oligonucleotide Conjugates Market Size Market Share
8.4 Europe
8.4.1 Europe Oligonucleotide Conjugates Market Size & Forecasts, 2020-2031
8.4.2 By Country, Europe Oligonucleotide Conjugates Market Size Market Share
8.5 Asia Pacific
8.5.1 Asia Pacific Oligonucleotide Conjugates Market Size & Forecasts, 2020-2031
8.5.2 By Country/Region, Asia Pacific Oligonucleotide Conjugates Market Size Market Share
8.6 South America
8.6.1 South America Oligonucleotide Conjugates Market Size & Forecasts, 2020-2031
8.6.2 By Country, South America Oligonucleotide Conjugates Market Size Market Share
8.7 Middle East & Africa

9 Sights by Country Level
9.1 By Country, Global Oligonucleotide Conjugates Market Size & CAGR，2020 VS 2024 VS 2031
9.2 By Country, Global Oligonucleotide Conjugates Market Size, 2020-2031
9.3 United States
9.3.1 United States Oligonucleotide Conjugates Market Size, 2020-2031
9.3.2 By Company, United States Oligonucleotide Conjugates Revenue Market Share, 2024
9.3.3 by Type, United States Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.3.4 by Application, United States Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.4 Europe
9.4.1 Europe Oligonucleotide Conjugates Market Size, 2020-2031
9.4.2 By Company, Europe Oligonucleotide Conjugates Revenue Market Share, 2024
9.4.3 by Type, Europe Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.4.4 by Application, Europe Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.5 China
9.5.1 China Oligonucleotide Conjugates Market Size, 2020-2031
9.5.2 By Company, China Oligonucleotide Conjugates Revenue Market Share, 2024
9.5.3 by Type, China Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.5.4 by Application, China Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.6 Japan
9.6.1 Japan Oligonucleotide Conjugates Market Size, 2020-2031
9.6.2 By Company, Japan Oligonucleotide Conjugates Revenue Market Share, 2024
9.6.3 by Type, Japan Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.6.4 by Application, Japan Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.7 South Korea
9.7.1 South Korea Oligonucleotide Conjugates Market Size, 2020-2031
9.7.2 By Company, South Korea Oligonucleotide Conjugates Revenue Market Share, 2024
9.7.3 by Type, South Korea Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.7.4 by Application, South Korea Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.8 Southeast Asia
9.8.1 Southeast Asia Oligonucleotide Conjugates Market Size, 2020-2031
9.8.2 By Company, Southeast Asia Oligonucleotide Conjugates Revenue Market Share, 2024
9.8.3 by Type, Southeast Asia Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.8.4 by Application, Southeast Asia Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.9 India
9.9.1 India Oligonucleotide Conjugates Market Size, 2020-2031
9.9.2 By Company, India Oligonucleotide Conjugates Revenue Market Share, 2024
9.9.3 by Type, India Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.9.4 by Application, India Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.10 Middle East & Africa
9.10.1 Middle East & Africa Oligonucleotide Conjugates Market Size, 2020-2031
9.10.2 By Company, Middle East & Africa Oligonucleotide Conjugates Revenue Market Share, 2024
9.10.3 by Type, Middle East & Africa Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031
9.10.4 by Application, Middle East & Africa Oligonucleotide Conjugates Revenue Market Share, 2024 VS 2031

10 Company Profile
10.1 WuXi TIDES
10.1.1 WuXi TIDES Company Information, Head Office, Market Area, and Industry Position
10.1.2 WuXi TIDES Company Profile and Main Business
10.1.3 WuXi TIDES Oligonucleotide Conjugates Models, Specifications, and Application
10.1.4 WuXi TIDES Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.1.5 WuXi TIDES Recent Developments
10.2 Bachem
10.2.1 Bachem Company Information, Head Office, Market Area, and Industry Position
10.2.2 Bachem Company Profile and Main Business
10.2.3 Bachem Oligonucleotide Conjugates Models, Specifications, and Application
10.2.4 Bachem Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.2.5 Bachem Recent Developments
10.3 Lonza
10.3.1 Lonza Company Information, Head Office, Market Area, and Industry Position
10.3.2 Lonza Company Profile and Main Business
10.3.3 Lonza Oligonucleotide Conjugates Models, Specifications, and Application
10.3.4 Lonza Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.3.5 Lonza Recent Developments
10.4 BioSpring
10.4.1 BioSpring Company Information, Head Office, Market Area, and Industry Position
10.4.2 BioSpring Company Profile and Main Business
10.4.3 BioSpring Oligonucleotide Conjugates Models, Specifications, and Application
10.4.4 BioSpring Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.4.5 BioSpring Recent Developments
10.5 GenScript
10.5.1 GenScript Company Information, Head Office, Market Area, and Industry Position
10.5.2 GenScript Company Profile and Main Business
10.5.3 GenScript Oligonucleotide Conjugates Models, Specifications, and Application
10.5.4 GenScript Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.5.5 GenScript Recent Developments
10.6 Medtide (CPC Scientific)
10.6.1 Medtide (CPC Scientific) Company Information, Head Office, Market Area, and Industry Position
10.6.2 Medtide (CPC Scientific) Company Profile and Main Business
10.6.3 Medtide (CPC Scientific) Oligonucleotide Conjugates Models, Specifications, and Application
10.6.4 Medtide (CPC Scientific) Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.6.5 Medtide (CPC Scientific) Recent Developments
10.7 Kaneka Corporation (Eurogentec)
10.7.1 Kaneka Corporation (Eurogentec) Company Information, Head Office, Market Area, and Industry Position
10.7.2 Kaneka Corporation (Eurogentec) Company Profile and Main Business
10.7.3 Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Models, Specifications, and Application
10.7.4 Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.7.5 Kaneka Corporation (Eurogentec) Recent Developments
10.8 Olon (GTP Bioways)
10.8.1 Olon (GTP Bioways) Company Information, Head Office, Market Area, and Industry Position
10.8.2 Olon (GTP Bioways) Company Profile and Main Business
10.8.3 Olon (GTP Bioways) Oligonucleotide Conjugates Models, Specifications, and Application
10.8.4 Olon (GTP Bioways) Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.8.5 Olon (GTP Bioways) Recent Developments
10.9 Abzena
10.9.1 Abzena Company Information, Head Office, Market Area, and Industry Position
10.9.2 Abzena Company Profile and Main Business
10.9.3 Abzena Oligonucleotide Conjugates Models, Specifications, and Application
10.9.4 Abzena Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.9.5 Abzena Recent Developments
10.10 3PBIOVIAN
10.10.1 3PBIOVIAN Company Information, Head Office, Market Area, and Industry Position
10.10.2 3PBIOVIAN Company Profile and Main Business
10.10.3 3PBIOVIAN Oligonucleotide Conjugates Models, Specifications, and Application
10.10.4 3PBIOVIAN Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.10.5 3PBIOVIAN Recent Developments
10.11 Bio-Synthesis Inc
10.11.1 Bio-Synthesis Inc Company Information, Head Office, Market Area, and Industry Position
10.11.2 Bio-Synthesis Inc Company Profile and Main Business
10.11.3 Bio-Synthesis Inc Oligonucleotide Conjugates Models, Specifications, and Application
10.11.4 Bio-Synthesis Inc Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.11.5 Bio-Synthesis Inc Recent Developments
10.12 ChemExpress
10.12.1 ChemExpress Company Information, Head Office, Market Area, and Industry Position
10.12.2 ChemExpress Company Profile and Main Business
10.12.3 ChemExpress Oligonucleotide Conjugates Models, Specifications, and Application
10.12.4 ChemExpress Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.12.5 ChemExpress Recent Developments
10.13 Creative Biolabs
10.13.1 Creative Biolabs Company Information, Head Office, Market Area, and Industry Position
10.13.2 Creative Biolabs Company Profile and Main Business
10.13.3 Creative Biolabs Oligonucleotide Conjugates Models, Specifications, and Application
10.13.4 Creative Biolabs Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.13.5 Creative Biolabs Recent Developments
10.14 HitGen
10.14.1 HitGen Company Information, Head Office, Market Area, and Industry Position
10.14.2 HitGen Company Profile and Main Business
10.14.3 HitGen Oligonucleotide Conjugates Models, Specifications, and Application
10.14.4 HitGen Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.14.5 HitGen Recent Developments
10.15 Pharmaron
10.15.1 Pharmaron Company Information, Head Office, Market Area, and Industry Position
10.15.2 Pharmaron Company Profile and Main Business
10.15.3 Pharmaron Oligonucleotide Conjugates Models, Specifications, and Application
10.15.4 Pharmaron Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.15.5 Pharmaron Recent Developments
10.16 Suzhou Biosyntech
10.16.1 Suzhou Biosyntech Company Information, Head Office, Market Area, and Industry Position
10.16.2 Suzhou Biosyntech Company Profile and Main Business
10.16.3 Suzhou Biosyntech Oligonucleotide Conjugates Models, Specifications, and Application
10.16.4 Suzhou Biosyntech Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.16.5 Suzhou Biosyntech Recent Developments
10.17 Creative Biogene (IntegrateRNA)
10.17.1 Creative Biogene (IntegrateRNA) Company Information, Head Office, Market Area, and Industry Position
10.17.2 Creative Biogene (IntegrateRNA) Company Profile and Main Business
10.17.3 Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Models, Specifications, and Application
10.17.4 Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Revenue and Gross Margin, 2020-2025
10.17.5 Creative Biogene (IntegrateRNA) Recent Developments

11 Conclusion

12 Appendix
12.1 Research Methodology
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Market Estimation Model
12.4 Disclaimer

According to YH Research, the global market for Oligonucleotide Conjugates should grow from US$ 180 million in 2024 to US$ 1691 million by 2031, with a CAGR of 37.9% for the period of 2025-2031.

Oligonucleotide conjugates (OCs) are a novel class of biomolecules formed by covalently binding oligonucleotide chains to functional molecules (such as small molecule drugs, antibodies, peptides, lipids, carbohydrates, and fluorescent probes) using chemical linking techniques. The core principle is to leverage the sequence-specific targeting capabilities of oligonucleotides and the functional advantages of the conjugate molecules to achieve a synergistic effect of "targeted delivery + precise action." These molecules combine the targeting precision of oligonucleotides with the functional diversity of the conjugate components, making them core carriers in gene therapy and precision diagnostics, and widely used in the treatment and detection of tumors, rare diseases, and infectious diseases.

Oligonucleotide Conjugates

According to YH Research, the global market for Oligonucleotide Conjugates should grow from US$ 180 million in 2024 to US$ 1691 million by 2031, with a CAGR of 37.9% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The global oligonucleotide conjugates market is experiencing rapid growth driven by the explosive demand from gene therapy and precision medicine, with its size and growth rate deeply tied to breakthroughs in delivery technology and drug commercialization. The oligonucleotide conjugate market is currently experiencing a golden age of rapid growth. 
The core drivers of growth come from two aspects: firstly, technological iterations have overcome application bottlenecks; the maturity of liver-targeted conjugate technology has propelled the commercialization of the first siRNA drug, Leqvio (inclisiran). Secondly, clinical pipelines are progressing rapidly, with over 80 oligonucleotide conjugates (OOCs) in clinical trials globally. Among these, three OOCs have entered Phase III clinical trials and are expected to launch in 2026-2027, triggering a significant market expansion.

In terms of product type, GalNAc conjugates, due to their specific binding to the ASGPR receptor on hepatocytes, have become the preferred technology for liver-related diseases, accounting for 51% of the gene therapy conjugate market. AOCs, combining the targeting ability of antibodies with the gene regulation capabilities of oligonucleotides, have become key to unlocking extrahepatic tissue delivery, with a market growth rate exceeding 37% by 2025.

The upstream of the industry chain focuses on the supply of high-purity oligonucleotide raw materials and functional conjugate molecules, with core technologies monopolized by international giants. Domestic companies are accelerating breakthroughs in achieving self-sufficiency in raw materials and conjugation reagents. The midstream is centered on CDMO services, with international giants Novartis and Alnylam dominating the commercial market with blockbuster products like Inccilan and Patigrelan. Domestic company Jiajin Bio is advancing its pipeline layout based on its independent technology platform. Downstream demand is concentrated in therapeutic areas such as oncology, rare diseases, and infectious diseases, as well as precision diagnostics. 
Gene therapy dominates the downstream market, and conjugate technology has solved the targeting and safety challenges of gene therapy, achieving breakthroughs in rare diseases and oncology. In the field of hereditary diseases, GalNAc-oligonucleotide conjugates have been approved for marketing in the treatment of acute hepatic porphyria; in the oncology field, AOCs can target Her2 and TROP2 antigens, delivering siRNA to silence oncogenes in cancer cells.

This report aims to provide a comprehensive study of the global market for Oligonucleotide Conjugates. Report Highlights:
(1) Global Oligonucleotide Conjugates market size (value), history data from 2020-2024, and forecast data from 2025 to 2031.

(2) Global Oligonucleotide Conjugates market competitive situation, revenue, and market share, from 2020 to 2024.

(3) China Oligonucleotide Conjugates market competitive situation, revenue, and market share, from 2020 to 2024.

(4) Global Oligonucleotide Conjugates segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global Oligonucleotide Conjugates segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Oligonucleotide Conjugates industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
    Oligonucleotide-Peptide
    Oligonucleotide-Antibody
    Oligonucleotide-Lipid
    Oligonucleotide-Toxin
    Oligonucleotide-GalNAc
    Other

Market segment by Oligonucleotide Types, covers
    siRNA
    ASO
    Others

Market segment by Application, can be divided into
    Gene Therapy
    Drug Delivery
    Vaccine Development

Market segment by players, this report covers
    WuXi TIDES
    Bachem
    Lonza
    BioSpring
    GenScript
    Medtide (CPC Scientific)
    Kaneka Corporation (Eurogentec)
    Olon (GTP Bioways)
    Abzena
    3PBIOVIAN
    Bio-Synthesis Inc
    ChemExpress
    Creative Biolabs
    HitGen
    Pharmaron
    Suzhou Biosyntech
    Creative Biogene (IntegrateRNA)